Delay in cell infusion improves GVHD and clinical outcomes in severe aplastic anemia patients >30 years receiving unrelated donor hematopoietic stem cell transplantation
Blood Cells, Molecules, and Diseases · 2026-07 · 119 · 103003
DOI: 10.1016/j.bcmd.2026.103003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Cells, Molecules, and Diseases, 2026-07. Verfasst von Jinrong Zhao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China; Department of Hematol…. Hauptthemen laut MEDLINE: Anemia, Aplastic, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Guangzhou Municipal Science and Technology Project.
Abstract (Originalsprache)
Circadian rhythms regulate immune cell activity, but their impact on hematopoietic stem cell infusion remains unclear. This retrospective study evaluated 177 severe aplastic anemia (SAA) patients undergoing unrelated donor hematopoietic stem cell transplantation (URD-HSCT) (2012-2023) to assess impacts of circadian infusion timing. No significant differences emerged between early and late infusion groups in cumulative incidence (CUI) of neutrophil/platelet engraftment, acute/chronic graft-versus-host disease (aGVHD/cGVHD), or CMV/EBV viremia. Notably, CUI of grade III-IV aGVHD was higher in the early group (5.7%, 95% CI: 1.8%-13.4%) versus 0% in the late group (95% CI: 0%-3.4%, P = 0.03). Five-year overall survival (OS: 87% vs. 93%, P = 0.1871), failure-free survival (FFS: 85% vs. 92%, P = 0.1389), and graft-versus-host disease/relapse-free survival (GRFS: 76% vs. 82%, P = 0.2781) showed no statistical disparities. Subgroup analysis revealed older patients (>30 years) receiving late peripheral blood HSCT had superior OS (78% vs. 97%, P = 0.0154) and FFS (78% vs. 94%, P = 0.0390). These data suggest that the timing of infusion may affect the risk of GVHD and the survival of older patients, for whom delayed infusion may confer a survival benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China; Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University,…
Förderung
- National Key Research and Development Program of China
- Guangzhou Municipal Science and Technology Project
Zitieren
APA
Zhao, J., Chen, X., Wu, L., Li, X., Mo, W., Zhou, R., Li, Y., Wang, C., Xu, S., Pan, S., Zhou, W., Deng, T., Wang, S., Zhang, Y., & Zhou, M. (2026). Delay in cell infusion improves GVHD and clinical outcomes in severe aplastic anemia patients >30 years receiving unrelated donor hematopoietic stem cell transplantation. Blood Cells, Molecules, and Diseases, 119, 103003. https://doi.org/10.1016/j.bcmd.2026.103003
Vancouver
Zhao J, Chen X, Wu L, Li X, Mo W, Zhou R, et al. Delay in cell infusion improves GVHD and clinical outcomes in severe aplastic anemia patients >30 years receiving unrelated donor hematopoietic stem cell transplantation. Blood Cells, Molecules, and Diseases. 2026;119:103003. doi:10.1016/j.bcmd.2026.103003
BibTeX
@article{Zhao2026,
author = {Zhao, Jinrong and Chen, Xiaowei and Wu, Liangliang and Li, Xinxin and Mo, Wenjian and Zhou, Ruiqing and Li, Yumiao and Wang, Caixia and Xu, Shilin and Pan, Shiyi and Zhou, Wei and Deng, Tingfen and Wang, Shunqing and Zhang, Yuping and Zhou, Ming},
title = {Delay in cell infusion improves GVHD and clinical outcomes in severe aplastic anemia patients >30 years receiving unrelated donor hematopoietic stem cell transplantation},
journal = {Blood Cells, Molecules, and Diseases},
year = {2026},
volume = {119},
pages = {103003},
doi = {10.1016/j.bcmd.2026.103003}
}
EUVIMED